http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 17 Aug 2026 16:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TransMedics+Group%2C+Inc.+++For%3A+Aug+17++Filed+by%3A+TOBIN+JAMES+R/26938559.html si-local-file:///var/storage/secattach/20260817/26938559.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TransMedics+Group%2C+Inc.+++For%3A+Aug+17++Filed+by%3A+TOBIN+JAMES+R/26938559.html Mon, 17 Aug 2026 16:45:00 -0400 O.00051745 TMDX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TransMedics+Group%2C+Inc.+++For%3A+Aug+17++Filed+by%3A+TOBIN+JAMES+R/26938559.html si-local-file:///var/storage/secattach/20260817/26938559.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TransMedics+Group%2C+Inc.+++For%3A+Aug+17++Filed+by%3A+TOBIN+JAMES+R/26938559.html Mon, 17 Aug 2026 16:45:00 -0400 O.00051745 TMDX http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%2477+at+UBS/26871555.html UBS analyst Patrick Wood lowered the price target on TransMedics Group (NASDAQ: TMDX) to $77.00 (from $80.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%2477+at+UBS/26871555.html Wed, 05 Aug 2026 09:37:10 -0400 TMDX http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%2465+at+Stifel/26870788.html Stifel analyst Thomas Stephan lowered the price target on TransMedics Group (NASDAQ: TMDX) to $65.00 (from $80.00) while maintaining a Hold rating. http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%2465+at+Stifel/26870788.html Wed, 05 Aug 2026 08:24:25 -0400 TMDX http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%2492+at+JPMorgan/26870761.html JPMorgan analyst Allen Gong lowered the price target on TransMedics Group (NASDAQ: TMDX) to $92.00 (from $100.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%2492+at+JPMorgan/26870761.html Wed, 05 Aug 2026 08:17:20 -0400 TMDX http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%24100+at+Piper+Sandler/26870106.html Piper Sandler analyst Matt O'Brien lowered the price target on TransMedics Group (NASDAQ: TMDX) to $100.00 (from $120.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%24100+at+Piper+Sandler/26870106.html Wed, 05 Aug 2026 07:03:42 -0400 TMDX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TransMedics+Group%2C+Inc.+++For%3A+Jun+30/26866639.html si-local-file:///var/storage/secattach/20260804/26866639.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TransMedics+Group%2C+Inc.+++For%3A+Jun+30/26866639.html Tue, 04 Aug 2026 16:16:00 -0400 O.00051745 TMDX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TransMedics+Group%2C+Inc.+++For%3A+Jun+30/26866639.html si-local-file:///var/storage/secattach/20260804/26866639.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TransMedics+Group%2C+Inc.+++For%3A+Jun+30/26866639.html Tue, 04 Aug 2026 16:16:00 -0400 O.00051745 TMDX http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS233956/TransMedics-Logo.jpg?id=OA2824499" title="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" alt="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" /> http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html Tue, 04 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS233956/TransMedics-Logo.jpg?id=OA2824499" title="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" alt="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" /> http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html Tue, 04 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS233956/TransMedics-Logo.jpg?id=OA2824499" title="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" alt="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" /> http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html Tue, 04 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS233956/TransMedics-Logo.jpg?id=OA2824499" title="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" alt="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" /> http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html Tue, 04 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TransMedics+Group%2C+Inc.+++For%3A+Aug+04/26866139.html si-local-file:///var/storage/secattach/20260804/26866139.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TransMedics+Group%2C+Inc.+++For%3A+Aug+04/26866139.html Tue, 04 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TransMedics+Group%2C+Inc.+++For%3A+Aug+04/26866139.html si-local-file:///var/storage/secattach/20260804/26866139.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TransMedics+Group%2C+Inc.+++For%3A+Aug+04/26866139.html Tue, 04 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on <chron>July 29, 2026</chron>, TransMedics granted non-qualified stock options to purchase an aggregate of 18,762 shares of its common stock and an aggregate of 12,414 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html Mon, 03 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on <chron>July 29, 2026</chron>, TransMedics granted non-qualified stock options to purchase an aggregate of 18,762 shares of its common stock and an aggregate of 12,414 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html Mon, 03 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on <chron>July 29, 2026</chron>, TransMedics granted non-qualified stock options to purchase an aggregate of 18,762 shares of its common stock and an aggregate of 12,414 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html Mon, 03 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on <chron>July 29, 2026</chron>, TransMedics granted non-qualified stock options to purchase an aggregate of 18,762 shares of its common stock and an aggregate of 12,414 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html Mon, 03 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%24106+at+Needham/26853823.html (Updated - August 3, 2026 7:12 AM EDT) <p>Needham analyst Mike Matson lowered the price target on TransMedics Group (NASDAQ: TMDX) to $106.00 (from $142.00) while maintaining a Buy rating.</p><p>The analyst commented: "We are shifting our organ transplant tracker to a quarterly publication from a monthly publication. Additionally, we have reviewed the performance of our prior trackers. Based on our prior trackers which included all three months of SRTR data for a given quarter, we accurately predicted whether TMDX would beat or miss consensus in 3 of 5 quarters (see Figure 1). Based on the SRTR data for April through June, http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%24106+at+Needham/26853823.html Mon, 03 Aug 2026 07:12:55 -0400 TMDX http://www.streetinsider.com/Analyst+Comments/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%24106+at+Needham/26853823.html (Updated - August 3, 2026 7:12 AM EDT) <p>Needham analyst Mike Matson lowered the price target on TransMedics Group (NASDAQ: TMDX) to $106.00 (from $142.00) while maintaining a Buy rating.</p><p>The analyst commented: "We are shifting our organ transplant tracker to a quarterly publication from a monthly publication. Additionally, we have reviewed the performance of our prior trackers. Based on our prior trackers which included all three months of SRTR data for a given quarter, we accurately predicted whether TMDX would beat or miss consensus in 3 of 5 quarters (see Figure 1). Based on the SRTR data for April through June, http://www.streetinsider.com/Analyst+Comments/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%24106+at+Needham/26853823.html Mon, 03 Aug 2026 07:12:55 -0400 TMDX http://www.streetinsider.com/Press+Releases/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the Canaccord Genuity 46^th Annual Growth Conference in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston</location> on <chron>Tuesday, August 11, 2026</chron>. The TransMedics management team will present beginning at <chron>2:00 p.m. ET</chron>/ <chron>1:00 p.m. CT</chron></p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html Tue, 28 Jul 2026 16:29:00 -0400 O.00051745 TMDX http://www.streetinsider.com/Press+Releases/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the Canaccord Genuity 46^th Annual Growth Conference in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston</location> on <chron>Tuesday, August 11, 2026</chron>. The TransMedics management team will present beginning at <chron>2:00 p.m. ET</chron>/ <chron>1:00 p.m. CT</chron></p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html Tue, 28 Jul 2026 16:29:00 -0400 O.00051745 TMDX http://www.streetinsider.com/PRNewswire/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the Canaccord Genuity 46^th Annual Growth Conference in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston</location> on <chron>Tuesday, August 11, 2026</chron>. The TransMedics management team will present beginning at <chron>2:00 p.m. ET</chron>/ <chron>1:00 p.m. CT</chron></p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html Tue, 28 Jul 2026 16:29:00 -0400 O.00051745 TMDX http://www.streetinsider.com/PRNewswire/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the Canaccord Genuity 46^th Annual Growth Conference in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston</location> on <chron>Tuesday, August 11, 2026</chron>. The TransMedics management team will present beginning at <chron>2:00 p.m. ET</chron>/ <chron>1:00 p.m. CT</chron></p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html Tue, 28 Jul 2026 16:29:00 -0400 O.00051745 TMDX http://www.streetinsider.com/New+Coverage/UBS+Starts+TransMedics+Group+%28TMDX%29+at+Neutral/26821265.html <p>UBS initiates coverage on TransMedics Group (NASDAQ: TMDX) with a Neutral rating and a price target of $80.00.</p> <p>For an analyst ratings summary and ratings history on TransMedics Group <a href="http://www.streetinsider.com/rating_history.php?q=TMDX">click here</a>. For more ratings news on TransMedics Group <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TMDX&amp;type=analyst">click here</a>.</p> <p>Shares of TransMedics Group closed at $74.28 yesterday.</p> http://www.streetinsider.com/New+Coverage/UBS+Starts+TransMedics+Group+%28TMDX%29+at+Neutral/26821265.html Tue, 28 Jul 2026 05:33:58 -0400 TMDX